Jennewein Biotechnologie GmbH acquires Arthus Mineralsprings Bad Hönningen

Jennewein Biotechnologie GmbH acquires Arthus Mineralsprings Bad Hönningen to build a new integrated fermentation and recovery plant for human milk oligosaccharides 

Jennewein Biotechnologie GmbH announces that it has acquired the former facilities of Arthus Mineralspring Company in Bad Hönningen (Rhineland-Palatine) to expand the production of human milk oligosaccharides (OLH). "We have been looking for some time for a suitable location to establish an integrated OLH fermentation and recovery plant near our current plant in Rheinbreitbach," said Dr. Stefan Jennewein (CEO and co-founder, Jennewein Biotechnologie). "With the expansion of our OLH portfolio, and the development of our OLH Mix product, we need at least five new fermentation and recovery lines," said Benedikt Engels.(Director of Operations, Jennewein Biotechnologie). "With the new plant, we will be able to produce additional OLH, expanding our current portfolio of two products (2'-fucosillactose and lacto- N - neo- tetraose) to include five more (3'-fucosyllactose, difucosyllactose, lacto- N- tetraose, 6 '-Sialillactose and 3'-sialillactose) ". The new integrated plant will combine fermentation and recovery, and will produce spray-dried OLH products. Jennewein Biotechnologie plans to build independent production lines for the manufacture of each of the new OLH products. "With fermenters of more than 200 m [3]each, the new plant will be one of the largest fermentation plants in central Europe, "added Stephan Michel (finance director of Jennewein Biotechnology).

A near Jennewein Biotechnologie:  
Jennewein Biotechnologie is an international industrial biotechnology company leader in the market that has a range of products in the field of complex oligosaccharides (OLH) and unusual monosaccharides. The company manufactures a wide range of innovative OLH products, such as 2'-fucosillactose, 3'-fucosillactose and lacto- N-tetraous. These unusual sugars are used in the food industry (specifically in foods for babies), pharmaceuticals and cosmetics. The manufacturing process involves very cutting-edge fermentation techniques. In 2015, the United States Food and Drug Administration (FDA) granted Jennewein Biotechnologie a license to market 2'-fucosillactose in the United States. This was followed by authorization to be marketed in the European Union in 2017 under the European Regulation on novel foods.

Read Similar Articles

0 Comments Write your comment

    1. Loading...